Latest news - summary

A/Prof Andrew Oar

Cutting-edge trial using stereotactic body radiotherapy in addition to modern chemotherapy to kill pancreatic cancer

13 September 2018: Pancreatic cancer could be treated using a new form of radiotherapy that delivers highly targeted doses of radiation to kill tumour cells with precision while minimising toxicity to surrounding cells. The MASTERPLAN clinical trial for high-risk and locally advanced pancreatic cancer patients has secured $1.5 million in funding from the Australian Department of Health as par... Read More
LIPID Trial Team

DIABETES: Vast Majority of Diabetes Patients are Disadvantaged

28 August 2018: Of the estimated 400 million people with diabetes globally 75% live in disadvantaged regions1. The incidence and prevalence of all common types of diabetes, Type 2 diabetes, Type 1 diabetes and gestational diabetes is increasing.  The personal and socioeconomic costs are enormous.  Adverse effects of Type 1 and Type 2 diabetes related to acute complications such as i... Read More
LIPID Trial Team

CARDIOVASCULAR: The LIPID Study is turning 20 - Celebrate With Us!

1 August 2018: We are celebrating the 20th Anniversary of the LIPID study findings from LIPID's primary publication in 1998 to today. We will hold a Symposium and Reception on 26 October at the University of Sydney, Holme Building (Program).   Registration and Lunch will at 12:00pm in the Cullen Room and afterwardsthere will be a reception from 4-5pmafter which will meet for dinne... Read More
Blood glucose monitoring

DIABETES: New review recommends policy changes and practical steps to improve diabetes care

25 July 2018: Blood glucose meters and test strips for self-monitoring of blood glucose (SMBG) are vital tools in diabetes care, particularly for people with Type 1 diabetes and insulin-treated Type 2 diabetes. However, they are often inaccessible to, and infrequently used by, those with diabetes in countries where healthcare resources are limited. In a very recent review article published in... Read More
Dr Mbathio Dieng with A/Prof Rachael Morton

GENERAL NEWS: Prof Keech awarded Vice Chancellor's Award for Excellence

30 July 2018 CTC Deputy Director, Prof Tony Keech, has been awarded the prestigious 2018 University of Sydney Vice Chancellor's Award for Research. One of three given for Research, the award was established to celebrate exceptional performance at the University. As a whole-of-University, peer-nominated reward program, the awards recognise impact, leadership, entrepreneurship, mentorship,... Read More

ONCOLOGY: $965,000 funding for COGNO trial

25 July 2018 $965,000 funding for COGNO trial The Cooperative Trials Group for Neuro-Oncology (COGNO) at the NHMRC Clinical Trials Centre, University of Sydney, has been awarded $965,000 as part of a funding package from CanTeen to give adolescent and young adult cancer patients access to cutting-edge treatment. Federal Health Minister Greg Hunt and youth cancer organisation CanTeen today a... Read More
Dr Mbathio Dieng with A/Prof Rachael Morton

HEALTH ECONOMICS: CTC Research Fellow wins Prestigious University of Sydney Prize

31 May 2018 Congratulations to the CTC's Mbathio Dieng, who has won a prestigious University of Sydney Faculty of Medicine Award for her PhD research into managing stress and fear of cancer recurrence in recovering, early-stage melanoma patients. Dr Dieng received the $4,000 Peter Bancroft Prize at a ceremony held on May 30 and is pictured here with her Supervisor, Associate Professor Rachael... Read More

NEONATOLOGY: CTC’s Life-Saving Placental Transfusion Study Wins National Award

16 May 2018 - The NHMRC Clinical Trials Centre's Professor William Tarnow-Mordi has received the Australian Clinical Trials Alliance 'Trial of the Year' Award, Australia's premier award recognising outstanding achievements in investigator-initiated clinical trials.  The Hon. Greg Hunt MP, Minister of Health, presented Prof. Tarnow-Mordi with his award at a ceremony held at the Royal ... Read More
Cell Culture

ONCOLOGY: The AUTO-CHECK study: Investigating the molecular determinants of AUTO-immunity and immune-related adverse events in advanced cancer patients treated with immune CHECKpoint inhibitors

Immune checkpoint inhibitors are active in a variety of cancers. The hypothesis of AUTOCHECK is that cancer patients with a genetic susceptibility to autoimmunity are more likely to experience immune-related adverse events (IRAEs) after treatment with immune checkpoint inhibitors. This study aims to determine: potential molecular 'flags' that can identify who is likely to develop an IRAE co... Read More